Items Tagged ‘Alcensa’

April 24, 2018

Alcensa Provides Longer Symptom Improvement than Xalkori in ALK-positive Lung Cancer

By

CancerConnect News: Alecensa (alectinib) provides longer symptom improvement than Xalkori (crizotinib) in ALK-positive non-small-cell lung cancer (NSCLC), according to results presented at the European Lung Cancer Congress in in Geneva, Switzerland.1 About ALK + NSCLC Lung cancer is the leading cause of cancer death in the U.S. and around the world, highlighting the importance of […]

View full entry

Tags: Alcensa, Alecensa, alk-positive, Lung Cancer, Lung Cancer - Non-Small Cell, non-small cell lung cancer, xalkori


November 13, 2017

Alcensa Precision Medicine Approved for (ALK) Positive Non-Small Cell Lung Cancer

By

The Food and Drug Administration granted regular approval to Alcensa (alectinib), for treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC), as detected by an FDA-approved test. In December 2015, Alcensa received accelerated approval for treatment of patients with ALK-positive metastatic NSCLC whose disease progressed on or who were intolerant […]

View full entry

Tags: Alcensa, alectinib, alk, anaplastic lymphoma kinase, crizotinib, Lung Cancer - Non-Small Cell, News, non-small cell lung cancer, nsclc, positive metastatic, Precision Cancer Medicine, xalkori